文献速递银屑病与炎症性皮肤病

阿达木单抗生物类似药与原研药治疗银屑病的效果比较

Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis.
PubMed 文献 · JAMA Dermatol · 2025-01-01

该研究基于英国和爱尔兰BADBIR注册数据库,模拟两项实用性临床试验,比较阿达木单抗生物类似药Amjevita和Imraldi与Humira在银屑病患者中的真实世界疗效。结果显示,无论是新起始治疗还是从Humira转换,生物类似药在12个月时达到PASI≤2和PASI≤4的概率与原研药均无显著差异。

要点

  • 新起始Amjevita或Imraldi与起始Humira相比,12个月PASI≤2和≤4的达标率无显著差异。
  • 从Humira转换至Amjevita或Imraldi与继续使用Humira相比,疗效结局同样无显著差异。
  • 生物类似药在真实世界银屑病治疗中疗效与原研药相当,支持临床广泛应用。

核心结论

  • Amjevita和Imraldi在银屑病新起始治疗及从Humira转换的患者中,疗效与Humira相当。

研究设计与样本

  • 基于BADBIR前瞻性药物警戒注册数据库,模拟2项靶向实用性临床试验。
  • 数据收集自2007年9月至2023年1月,分析时间为2023年1月至9月。

主要发现

  • 新用药患者中,Amjevita与Humira相比达到PASI≤2的aOR为0.98(95%CI 0.78-1.25),Imraldi为0.83(95%CI 0.64-1.07)。
  • 新用药患者中,Amjevita与Humira相比达到PASI≤4的aOR为1.07(95%CI 0.84-1.37),Imraldi为0.91(95%CI 0.69-1.20)。
  • 转换患者中,Amjevita与继续Humira相比达到PASI≤2的aOR为1.19(95%CI 0.94-1.51),Imraldi为0.92(95%CI 0.72-1.18)。
  • 转换患者中,Amjevita与继续Humira相比达到PASI≤4的aOR为1.32(95%CI 0.96-1.84),Imraldi为1.00(95%CI 0.70-1.41)。

临床怎么用

  • 临床可考虑将Amjevita或Imraldi作为Humira的等效替代用于银屑病治疗。
  • 对于已稳定使用Humira超过2年的患者,转换至上述生物类似药未显示疗效劣势。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The uncertainties about the real-world effectiveness of adalimumab biosimilars limit their widespread adoption for psoriasis. OBJECTIVE: To compare the effectiveness of adalimumab biosimilars Amjevita and Imraldi with Humira for psoriasis. DESIGN, SETTING, AND PARTICIPANTS: An emulation of 2 targeted pragmatic clinical trials was conducted using data from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR), a prospective pharmacovigilance registry tracking individuals receiving biologic and conventional systemic treatments for psoriasis in the UK and the Republic of Ireland. Data from patients with psoriasis using adalimumab registered to BADBIR were included. Data were collected from September 2007 to January 2023, and data were analyzed from January to September 2023. EXPOSURES: The effectiveness of initiating Amjevita and Imraldi were compared with initiating Humira among adalimumab-naive patients, and the effectiveness of switching from Humira to either Amjevita or Imraldi were compared with continuing Humira among patients who had been using Humira consistently for more than 2 years. MAIN OUTCOMES AND MEASURES: The study outcomes were absolute Psoriasis Area and Severity Index (PASI) score of 2 or less and PASI score of 4 or less at 12 months after the index date. Inverse propensity treatment weighting was used to analyze receiving either biosimilars or Humira to account for confounding. Multiple imputations were used to account for missing PASI data at 12 months and inverse probability of censoring weighting to account for censorship due to deviation from the treatments under investigation. Logistic regression models were fitted to compare the outcomes between study cohorts. RESULTS: Of 11 400 included patients, 6924 (60.7%) were male, and the mean (SD) age was 45.3 (12.5) years. A total of 6133 patients were identified in the new user analysis (5416 starting Humira, 382 starting Amjevita, and 335 starting Imraldi) and 5267 patients in the switcher analysis (3808 continuing Humira, 847 switching to Amjevita, and 612 switching to Imraldi). Amjevita and Imraldi new users had no significantly different probability of achieving a PASI score of 2 or less (Amjevita: adjusted odds ratio [aOR], 0.98; 95% CI, 0.78-1.25; Imraldi: aOR, 0.83; 95% CI, 0.64-1.07) and a PASI score of 4 or less (Amjevita: aOR, 1.07; 95% CI, 0.84-1.37; Imraldi: aOR, 0.91; 95% CI, 0.69-1.20) compared with Humira new users. Patients who switched to Amjevita and Imraldi also had no statistically significant differences in achieving a PASI score of 2 or less (Amjevita: aOR, 1.19; 95% CI, 0.94-1.51; Imraldi: aOR, 0.92; 95% CI, 0.72-1.18) and a PASI score of 4 or less (Amjevita: aOR, 1.32; 95% CI, 0.96-1.84; Imraldi: aOR, 1.00; 95% CI, 0.70-1.41) compared with those who continued Humira. CONCLUSIONS AND RELEVANCE: In this study, Amjevita and Imraldi were as effective as Humira for both new starters and patients switching to biosimilars from Humira.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Phan DB, Bewley AP, Laws P, et al. Effectiveness of Adalimumab Biosimilars and Originator for Psoriasis. JAMA Dermatol. 2025. PMID: 40042863. doi:10.1001/jamadermatol.2025.0055

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。